SREBF1 and neoplasm: A novel anti-beta2-microglobulin monoclonal antibody decreases cell proliferation, induces massive cell death, and decreases AR expression via inhibition of SREBP-1-mediated fatty acid synthesis in the models of multiple PCa cell lines and xenograft tumor (150).